Sexual dysfunction outcomes and reporting disparities after multimodal treatment for rectal cancer: A systematic review and narrative synthesis Authors: Vignesh Lakshmanan, Jennifer Waterman, Alun Meggy, Jared Torkington, Julie A. Cornish Published: 2026 ABSTRACT AbstractBackgroundSexual dysfunction is a recognised adverse outcome after rectal cancer treatments, yet reporting is predominantly male‐focused, with female sexual dysfunction less consistently assessed or reported. This systematic review aimed to assess sexual health domains studied, examine sex‐based reporting disparities, and identify limitations in the current evidence.MethodsA systematic review and narrative synthesis were conducted in accordance with PRISMA and registered with PROSPERO (CRD420251178502). PubMed/MEDLINE, EMBASE, Scopus, CINAHL Plus, PsycINFO, and Cochrane Library were searched from March 1995 to March 2025, with an updated search to March 2026. Eligible studies included adults treated for rectal cancer in whom sexual function outcomes were assessed using International Index of Erectile Function (IIEF) and/or Female Sexual Function Index (FSFI), with additional related patient‐reported outcome measures (PROMs) accepted where relevant. Risk of bias was assessed using RoB 2 and MINORS.ResultsTwenty‐five studies involving 4,071 patients were included. Participants were predominantly male (65.8%), while women comprised 34.2%. PROM reporting was inconsistent; only eight studies reported both total and domain‐level results. Sexual outcomes were most consistently reported for men, particularly erectile and ejaculatory function, whereas female outcomes were often reduced to overall scores. Five studies restricted sexual outcome assessment and analysis to men. Only six reported response rates, and missing PROM data handling was not described. Key contextual variables, including sexual activity, sexual orientation, sexual practices, and menopausal status, were rarely captured.ConclusionsSexual function outcomes after rectal cancer treatment are inconsistently reported, with low certainty. Female sexual dysfunction remains under‐represented. Standardised, inclusive sex‐specific reporting and development of a core outcome set are needed. What does this paper add to the literature?This systematic review highlights important sex‐based reporting disparities in rectal cancer survivorship. It shows that women remain underrepresented, female sexual dysfunction and associated clinical factors are inconsistently assessed, and current outcome reporting lacks standardisation which limits equitable understanding of survivorship after rectal cancer treatment. What does this paper add to the literature? This systematic review highlights important sex‐based reporting disparities in rectal cancer survivorship. It shows that women remain underrepresented, female sexual dysfunction and associated clinical factors are inconsistently assessed, and current outcome reporting lacks standardisation which limits equitable understanding of survivorship after rectal cancer treatment. INTRODUCTION Colorectal cancer is the fourth most common cancer in the United Kingdom, accounting for approximately 11%, and rectal cancer represents around one‐quarter of diagnoses [1]. Advances in multimodal, curative‐intent treatments have improved oncological outcomes and survival [2, 3, 4]. However, treatment‐related morbidity varies, and sexual dysfunction is a well‐recognised adverse outcome that can substantially affect quality of life and psychosocial wellbeing [5, 6, 7, 8]. As survival has improved, attention has increasingly turned to long‐term quality of life (QoL) outcomes, including genitourinary and sexual dysfunction following surgery, radiotherapy, and other treatments for rectal cancer [9, 10]. Existing literature has predominantly focused on male sexual outcomes (mainly erectile and ejaculatory dysfunction), while female sexual outcomes (including dyspareunia, vaginal dryness and reduced desire) are less consistently studied [11, 12, 13]. Lee et al. [14] highlighted sex‐based disparities in rectal cancer surgery and noted that much of the sexual dysfunction literature remains male‐centred. Female sexual dysfunction has often been relatively overlooked and under‐reported, with some studies suggesting that women's reluctance to discuss sexual issues may contribute to this underrepresentation [8, 15, 16]. Sexual wellbeing is often a multifactorial late effect of cancer treatment; however, it may be overlooked in routine follow‐up, and patients may be reluctant to raise concerns. A report from the cancer charity, Macmillan, highlights that sexual function‐related problems can be forgotten or not discussed despite their impact on quality of life [17]. International survivorship guidance, from the National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO) recommendations emphasise routine, multidomain assessment of sexual health, including psychosocial context and distress as part of comprehensive survivorship care [18, 19]. Despite this, evidence of sexual health outcomes in rectal cancer management remains sparse and is often obscured by the lack of inclusive collection of data such as sexual orientation, practices, preferences, and menopause status within cancer services [20, 21, 22]. There is increasing need for studies that comprehensively assess sexual function, intimacy, sexual orientation, and sexual practices [23, 24]. This systematic review therefore aimed to synthesise the available evidence on sexual dysfunction after rectal cancer treatment, explore sex‐based reporting disparities, and identify priorities for inclusive, patient‐centred research. Review Question(s): What are the differences in the reporting and assessment of sexual dysfunction between male and female participants after rectal cancer treatments?What domains of sexual dysfunction are assessed by the Patient‐Reported Outcome Measures (PROMs) used in these studies? What are the differences in the reporting and assessment of sexual dysfunction between male and female participants after rectal cancer treatments? What are the differences in the reporting and assessment of sexual dysfunction between male and female participants after rectal cancer treatments? What domains of sexual dysfunction are assessed by the Patient‐Reported Outcome Measures (PROMs) used in these studies? What domains of sexual dysfunction are assessed by the Patient‐Reported Outcome Measures (PROMs) used in these studies? METHODS This systematic review and narrative synthesis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, following a protocol that was developed and approved by all authors in advance. The protocol was prepared a priori in line with the PRISMA‐P recommendations and registered with PROSPERO (International Prospective Register of Systematic Reviews) (CRD420251178502). Data selection Eligibility was defined using the PICOS framework. Population: Adult patients (≥18 years) diagnosed and who underwent treatment for rectal cancer. Intervention: Rectal cancer treatments, including but not limited to surgery, radiotherapy, chemotherapy. Comparisons: Studies were deemed eligible independently of head‐to‐head comparisons. Outcomes: Studies were eligible if they reported sexual function outcomes using validated or clearly described PROMs. This included International Index of Erectile Function (IIEF) and/or the Female Sexual Function Index (FSFI), as well as broader cancer‐related QoL instruments where sexual function domains or items were extractable. IIEF and FSFI were included because they were the most commonly used sexual function‐specific PROMs in the rectal cancer literature. As included studies reported outcomes by male/female classification rather than gender identity, we use “sex‐based” terminology, with “gender” retained only for broader contextual factors. Study design: Eligible study designs included randomised controlled trials, prospective or retrospective cohort studies, comparative observational studies, cross‐sectional studies, and non‐comparative observational cohorts where sexual function outcomes were systematically assessed using validated or clearly described PROMs. Studies were excluded if they met at least one of the following criteria: (a) included patients less than 18 years, (b) included colon or anal cancer without clear distinction of rectal cancer patients, (c) focused on palliative care or non‐curative treatments, (d) not published in English, (e) case reports, case series, letters, editorials, conference abstracts, commentaries, and reviews, (f) full‐text unavailable, (g) secondary research, such as systematic reviews or meta‐analyses. In cases of overlapping populations between studies, the study with the largest sample size and longest follow‐up was included. The initial search covered records from the last 30 years (March 14, 1995–March 14, 2025). An updated search was conducted prior to submission until March 25, 2026. Studies were assessed for eligibility through searches of the PubMed/MEDLINE, EMBASE, Scopus, CINAHL Plus, PsycINFO, and Cochrane Library databases. The pre‐defined complete search strategy is available in File S1. Data extraction Two reviewers (VL, JW) independently extracted data using a standardised form, piloted on a subset of studies. Disagreements were resolved with a third reviewer (JC). Extracted data included study characteristics, demographics, treatment, follow‐up and PROM outcomes. Corresponding authors were contacted for missing relevant data. Quality assessment Methodological quality was independently assessed by VL and JW using RoB 2 for randomised trials and MINORS for observational studies (File S2). The first eight MINORS items were applied to non‐comparative studies and all 12 to comparative studies. Scores were classified as high (≥13/16 or ≥19/24), moderate (9–12/16 or 13–18/24), or low (≤8/16 or ≤12/24) quality. Adequate follow‐up was pre‐specified as 12 months postoperatively. Certainty was assessed narratively according to risk of bias, consistency, directness, precision and reporting completeness. Response and PROM‐completion rates, where reported, informed interpretation; low or unreported completion was considered a potential source of response bias. Data analysis A narrative synthesis of sexual dysfunction outcomes was performed to present the findings of studies, following the European Social Research Council Guidance on the Conduct of Narrative Synthesis in Systematic Reviews and the Synthesis Without Meta‐analysis (SWiM) guideline [25, 26]. Data were summarised using numbers and percentages, where appropriate. Studies were grouped by PROM type, sex‐specific reporting, treatment modality, and timing of outcome assessment, with synthesis focused on patterns of reporting, direction of findings, and completeness of sex‐specific outcome data rather than pooled effect estimates. RESULTS Study selection A total of 2,467 records were identified. After removing 918 duplicate records, 1,549 records were screened based on titles and abstracts. Of these, 1,358 records were excluded. Ninety‐four full‐text articles were assessed for eligibility. Following full‐text review, 21 studies met the inclusion criteria (Figure 1). The updated search from March 14, 2025, to March 25, 2026, yielded 31 records, and four were eligible, giving a final total of 25 included studies (Figure 1). Flowchart depicting study selection. Study characteristics A total of 25 studies comprising 4,071 patients were included, with sample sizes ranging from 40 to 948 participants. Mean age ranged from 53 to 66 years, and 65.8% were male. Twelve studies were prospective, 11 retrospective, and two randomised controlled trials. Six were multicentre studies. Follow‐up ranged from weeks to 4 years. Study characteristics and quality assessments are presented in Tables 1, 2, 3. TABLE 1Demographics of the included studies.Author(s)YearCountryStudy settingStudy designStudy period (yyyy or mm/yyyy)No. of patientsAgeFollow‐upTimepointsResponse rateMeanMedianMaleFemaleAcquati et al.2022USAMCPS08/2014–12/20174053.2NRNRB, PR, PC, 4w85%85%Adam et al.2016UKSCPS2008–2012169NR6112 mB, PR, 3 m, 12 mNRNRAttaallah et al.2014TurkeySCRS01/2012–09/201384NR60NRSingle surveyNRNRAu et al.2012TaiwanSCRS07/2008–01/200912060.8NRNRSingle surveyNRNRBjoern et al.2022DenmarkMCPS TaTME: 08/2016–04/2019 LaTME/RoTME: 01/2011–09/2014 207NR TaTME: 69 LaTME/RoTME: 67.5 TaTME: 12 m LaTME/RoTME: 6 m TaTME: B, 3 m, 12 m LaTME/RoTME: B, 30d, 6 m 28.3%18.3%Dulskas et al.2016LithuaniaSCPS01/2008–12/20145460.04NR6 mB, 6 mNRNRDuran et al.2015TurkeySCPS08/2008–12/201056NRNR4 mB, 3 mNRNRGrass et al.2021Germany, Italy, TaiwanMCPS01/2014–02/201812062.9NR12 m12 mNRNRGurbanov et al.2025TurkeySCRS03/2017–12/2021100 Ro: 58.09 Lap: 60.55 NR Ro: 12.77 m Lap: 30.68 m 3 m, 6 m, 12 mNRNRHendren et al.2005CanadaSCRS1980–2003180NR60NRSingle survey80.5%81%Kim et al.2018KoreaSCRS2009–201326060.25NRNRB, 3 m, 6 m, 12 mNRNRLaohawiriyakamol et al.2022ThailandSCPS01/2014–12/201691NRNR12 mB, 3 m, 12 mNRNRLi et al.2021ChinaSCPS01/2012–08/201994853.7NR12 mB, 12 mNRNRLiu et al.2022ChinaSCPS01/2017–01/202013558.68NR12 mB, 1 m, 3 m, 6 m, 12 mNRNRLiu et al.2025ChinaSCRS01/2020–03/2023235 Ro: 63 Lap: 64 NR24 mB, 3 m, 6 m, 12 m, 24 m68.4%68.8%Macháčková et al.2022Czech RepublicSCRS03/2016–06/20186661.5NR24 mB, 3 m, 6 m, 12 m, 24 mNRNRMercieca‐Bebber et al.2023AustraliaMCRCT2010–2014473NR6512 mB, 4‐6w, 3 m, 12 m85.2%90.1%Numata et al.2025JapanMCPS01/2014–03/201713563.6; 62.3NR12 mB, 3 m, 6 m, 12 mNRNRPang et al.2020USASCRS2005–201647NRNRNRSingle surveyNRNRPontallier et al.2016FranceSCRCT06/2008–02/201272NR6212 mB, 12 mNRNRRooney et al.2024USASCRS01/2017–12/202047NRNRNRSingle surveyNRNRSharabiany et al.2022Netherlands and UKMCRS Netherlands: 2001–2018 UK: 2010–2018 12564NRNRB, Post‐opNRNRTorrijo et al.2021SpainSCPS01/2017–03/20198066.36NR12 mB, 6 m, 12 mNRNRTschann et al.2022AustriaSCRS01/1998–12/202079NR76NRSingle surveyNRNRWong et al.2025ChinaSCPS01/2016–12/2021148Ro: 67.5, Ta: 64.512 m1 m, 3 m, 6 m, 12 m96.5%NRTotal4,071Abbreviations: #, Number; B, Baseline; LaTME, Laparoscopic Total Mesorectal Excision; m, month(s); MC, Multicentre; NR, Not reported; PC, Post Chemotherapy; PR, Post Radiotherapy; PS, Prospective Study; RCT, Randomised Controlled Trial; Ro, Robotic; RoTME, Robotic Total Mesorectal Excision; RS, Retrospective Study; SC, Single Centre; Ta, Transanal; TaTME, Transanal Total Mesorectal Excision; w, week(s). Demographics of the included studies. TaTME: 08/2016–04/2019 LaTME/RoTME: 01/2011–09/2014 TaTME: 69 LaTME/RoTME: 67.5 TaTME: 12 m LaTME/RoTME: 6 m TaTME: B, 3 m, 12 m LaTME/RoTME: B, 30d, 6 m Ro: 58.09 Lap: 60.55 Ro: 12.77 m Lap: 30.68 m Ro: 63 Lap: 64 Netherlands: 2001–2018 UK: 2010–2018 Abbreviations: #, Number; B, Baseline; LaTME, Laparoscopic Total Mesorectal Excision; m, month(s); MC, Multicentre; NR, Not reported; PC, Post Chemotherapy; PR, Post Radiotherapy; PS, Prospective Study; RCT, Randomised Controlled Trial; Ro, Robotic; RoTME, Robotic Total Mesorectal Excision; RS, Retrospective Study; SC, Single Centre; Ta, Transanal; TaTME, Transanal Total Mesorectal Excision; w, week(s). TABLE 2Quality assessment of the included non‐randomised studies using the Modified Methodological Items for Non‐Randomised Studies (MINORS).Study123456789101112TotalQualityAcquati et al. [27] 2 1 2 2 1 1 0 0 Additional criteria in ccc coo comparative study9/16ModerateAdam et al. [28] 2 2 2 2 1 2 0 0 11/16ModerateAttaallah et al. [29] 2 1 1 2 1 0 0 0 7/16LowAu et al. [30] 2 1 1 2 1 0 1 2 10/16ModerateBjoern et al. [31] 1 2 2 2 1 2 0 0 2 1 1 1 13/24ModerateDulskas et al. [32] 2 1 2 2 1 1 0 0 9/16ModerateDuran et al. [33] 2 2 2 2 1 1 2 2 14/16HighGrass et al. [34] 2 2 2 2 1 2 1 0 2 2 1 2 19/24HighGurbanov et al. [35] 2 1 0 2 1 2 0 0 2 2 1 2 15/24ModerateHendren et al. [15] 2 1 0 2 1 2 0 0 8/16LowKim et al. [36] 2 2 2 2 1 2 1 0 2 2 2 2 20/24HighLaohawiriyakamol et al. [37] 2 2 2 2 1 2 1 0 12/16ModerateLi et al. [38] 2 2 2 2 2 2 1 0 13/16HighLiu et al. [39] 2 2 2 2 1 2 2 2 2 2 2 2 23/24HighLiu et al. [40] 2 1 0 2 1 2 0 0 2 2 1 2 15/24ModerateMacháčková et al. [41] 2 2 2 2 1 2 1 0 2 2 2 1 19/24HighNumata et al. [42] 2 2 2 2 1 2 1 0 2 2 1 1 18/24ModeratePang et al. [43] 2 1 0 2 1 2 0 0 8/16LowRooney et al. [44] 2 1 0 2 1 2 0 0 2 2 2 1 15/24ModerateSharabiany et al. [45] 2 1 0 2 1 2 0 0 8/16LowTorrijo et al. [46] 2 2 2 2 1 2 1 0 12/16ModerateTschann et al. [47] 2 1 0 2 1 2 0 0 8/16LowWong et al. [48] 2 2 1 2 1 2 0 0 2 2 2 1 17/24Moderate Note: MINORS items 1–8 apply to all studies, while items 9–12 apply only to comparative studies; therefore, the maximum possible score is 16 for non‐comparative studies and 24 for comparative studies. Each item is scored as 0 = not reported, 1 = reported but inadequate, and 2 = reported and adequate. Colour coding: green = 2, yellow = 1, and red/pink = 0. For the overall quality classification, green, yellow, and red/pink indicate high, moderate, and low methodological quality, respectively. Quality assessment of the included non‐randomised studies using the Modified Methodological Items for Non‐Randomised Studies (MINORS). Note: MINORS items 1–8 apply to all studies, while items 9–12 apply only to comparative studies; therefore, the maximum possible score is 16 for non‐comparative studies and 24 for comparative studies. Each item is scored as 0 = not reported, 1 = reported but inadequate, and 2 = reported and adequate. Colour coding: green = 2, yellow = 1, and red/pink = 0. For the overall quality classification, green, yellow, and red/pink indicate high, moderate, and low methodological quality, respectively. TABLE 3Risk of bias (RoB 2) assessment for randomised controlled trials.Study (year)Domain 1Domain 2Domain 3Domain 4Domain 5Overall riskMercieca‐Bebber et al. [49]LowLowLowSomeLowSomePontallier et al. [50]LowSomeLowSomeLowSome Note: RoB 2 judgements are abbreviated in the table as Low, Some, and High. These correspond to the official RoB 2 categories “Low risk of bias”, “Some concerns”, and “High risk of bias”, respectively. Domain 1: Randomisation process; Domain 2: Deviations from intended interventions; Domain 3: Missing outcome data; Domain 4: Measure of the outcome; Domain 5: Selection of the reported results Color coding: green = low risk of bias, yellow = some concerns, and red/pink = high risk of bias. Risk of bias (RoB 2) assessment for randomised controlled trials. Note: RoB 2 judgements are abbreviated in the table as Low, Some, and High. These correspond to the official RoB 2 categories “Low risk of bias”, “Some concerns”, and “High risk of bias”, respectively. Domain 1: Randomisation process; Domain 2: Deviations from intended interventions; Domain 3: Missing outcome data; Domain 4: Measure of the outcome; Domain 5: Selection of the reported results Color coding: green = low risk of bias, yellow = some concerns, and red/pink = high risk of bias. Narrative synthesis Due to the considerable heterogeneity among the included studies, a quantitative meta‐analysis was not feasible. Therefore, a narrative synthesis was undertaken to summarise the findings. Domains of sexual dysfunction and PROMs used Most studies incorporated validated PROMs, but instrument selection varied considerably (Figure 2), and these were utilised selectively or without domain‐specific reporting. Thirteen studies used the shorter versions of IIEF (IIEF‐5, a five‐item instrument) [29, 36, 37, 38, 39, 40, 41, 42, 44, 46, 47, 48, 50], which primarily assesses erectile function with one item relating to intercourse satisfaction, compared to IIEF‐15, which assesses multiple domains such as orgasmic function, sexual desire, or overall satisfaction. For female sexual health, different or adapted versions of FSFI were used. Six studies used FSFI‐6 [28, 31, 37, 38, 47, 50], with one study using FSFI‐9 [32], IFSF [33], IFSI [29], and the rest of the studies used FSFI‐19. Frequency of patient‐reported outcome measure (PROM) use across included studies (n = 25). Bars represent the percentage of included studies using each PROM. Different versions of the IIEF and FSFI were grouped under their respective parent instruments. Additional PROMs were used to assess urinary or bowel function, including the International Prostate Symptom Score (IPSS) [31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 48, 50], Bristol Female Lower Urinary Tract Symptoms (BFLUTS) [32], Low Anterior Resection Syndrome (LARS) score [31, 34, 35, 47, 50], International Consultation on Incontinence Questionnaire—Male Lower Urinary Tract Symptoms (ICIQ‐MLUTS) [31, 34, 44], and International Consultation on Incontinence Questionnaire—Female Lower Urinary Tract Symptoms (ICIQ‐FLUTS) [31, 34, 44]. Others used broad quality‐of‐life measures such as EORTC QLQ‐C30 [31, 36, 47], EORTC QLQ‐CR29 [45, 49], EORTC QLQ‐CR38 [15], or SF‐36 [31], which contain limited sexual health items. Sex representation Sex representation imbalance was evident across almost all studies. Participants were predominantly male (2,679/4,071; 65.8%) with females representing 1,392/4,071 (34.2%) (Figure 3). At the study level, female representation ranged from 22% to 50% (median 35%), although the upper bound (50%) was observed in one study [27] where participants were enrolled as heterosexual couples, resulting in balanced sex distribution by study design; in the remaining studies, women comprised approximately one‐quarter to one‐third of participants. The proportion of male participants ranged from 50% to 78%, with six studies reporting >70% male population predominance [30, 31, 36, 42, 45, 48]. Sex distribution by study. Comparability and assessment Most studies incorporated a baseline assessment (B) with follow‐up clustered around the first postoperative year, commonly at 3 months (3 m) and 12 months (12 m) [28, 36, 37, 39, 40, 41, 48, 49]; two studies included earlier post‐treatment assessments such as post‐radiotherapy (PR) and post‐chemotherapy (PC) [27, 28]. One study reported procedure‐specific follow‐up schedules, using different timepoints depending on the operative approach [31]. Six studies used single cross‐sectional surveys without repeated measurements [15, 29, 30, 43, 44, 47]. Stratified subgroup analyses were reported in four studies based on surgical intervention [34, 36, 41, 50], and [44] based on stoma status. Sexual activity status, sexual preference, and menopausal status were rarely reported. Reporting disparities Patient‐reported outcome measures (PROMs) reporting was inconsistent, and overall domain granularity was uncommon across studies, with a clear skew towards reporting total scores rather than detailed domains. Fourteen studies reported total scores only [29, 33, 35, 36, 37, 38, 39, 40, 41, 42, 44, 47, 48, 50], without domain‐specific details. Eight studies reported both total and domain‐level results [15, 27, 30, 31, 32, 34, 43, 45], while only three provided domain‐level reporting [28, 46, 49]. All studies reported male and female sexual function separately, except [36, 42, 48], which restricted sexual function assessment and analysis to male patients only. Thirteen studies reported adjusted analyses accounting for covariates, including two propensity score‐matched analyses [36, 48]. Of these, two studies [28, 37] restricted adjusted modelling to the male cohort, with female sexual outcomes not included in multivariable analyses and no clear justification provided. Six studies [15, 27, 31, 40, 48, 49] reported on response rates. Only one study reported sexual function‐related PROMs filling rate [40]. For studies with repeated time points, response rates at each follow‐up assessment were not reported in any studies. Methods for handling missing PROMs data (e.g., complete‐case analysis or imputation) were not reported. Eight studies placed greater reporting emphasis on male outcomes [31, 36, 37, 42, 43, 46, 48, 50]. Small female sample size was reported in 16/25 studies [28, 29, 30, 32, 33, 34, 37, 38, 42, 43, 44, 45, 46, 47, 48, 50]. Among these, two studies explicitly noted that women were under‐represented [30, 34], and four studies reported reluctance among female participants to complete sexual function PROMs [28, 37, 38, 50]. DISCUSSION This systematic review of 25 studies involving 4,071 patients found that sexual function outcomes after multimodal rectal cancer treatment were assessed inconsistently and reported with clear sex‐based disparities. The evidence base was male‐predominant and often male‐oriented, with sexual outcomes most consistently reported for men, particularly erectile and ejaculatory function. In contrast, female sexual function was commonly condensed to overall scores, and in some studies, the female cohort was excluded from sexual outcome analyses or multivariable models without justification [28, 36, 37, 42, 48]. These findings suggest that the current survivorship evidence disproportionately reflects male sexual outcomes and may provide a less complete account of female sexual health after rectal cancer treatment. This contrasts with survivorship guidance (NCCN, ASCO, Macmillan Cancer Support) that advocates proactive, routine and inclusive assessment of sexual health [9, 17, 18, 19]. These findings are best interpreted as sex‐based reporting disparities rather than evidence of systematic bias. The review did not assess causal mechanisms or author intent, and the observed disparities may reflect smaller female samples, lower PROM completion, or broader methodological limitations. Under‐representation and selective inclusion Women constituted approximately one‐third of participants overall, and many studies (16/25) explicitly reported small female samples, limiting statistical power for sex‐based comparisons. However, limited sample size alone does not fully explain the reporting gap. Even when women were included, female sexual outcomes were frequently presented with less detail than male outcomes, and adjusted modelling was sometimes restricted to men. Five studies omitted sexual function analysis in women while including women in other QoL measures without clear justification. Contemporary incidence data show male predominance in rectal cancer globally and in UK bowel cancer statistics [1]; therefore, the lower female proportion in this review may partly reflect epidemiology, although limited female‐specific PROM use, reduced domain‐level reporting, and exclusion from some analyses suggest that epidemiology alone does not explain the reporting gap. This pattern aligns with broader survivorship literature in colorectal and pelvic cancers, where female sexual dysfunction is often described as comparatively under‐studied, variably defined, and supported by less developed evidence for targeted interventions [51, 52, 53, 54], leaving female outcomes less certain and less comparable. There is no data reported on sexual orientation as part of these studies, which may have relevance when considering use of the FSFI score, which specifically defines sexual intercourse as “penile penetration (entry) of the vagina” and could impact on response rates. Limited female domain granularity and measurement limitations A further consistent finding was reliance on the IIEF, particularly IIEF‐5, which largely emphasises erectile and ejaculatory function. Female outcomes were assessed using a range of FSFI versions and adaptations such as FSFI‐6, FSFI‐9, FSFI‐19, IFSF, and IFSI, but were commonly reported as total scores rather than domain‐level results. The lack of domain granularity in female reporting limits interpretability, as clinically relevant domains (e.g., desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia) may be differentially affected by pelvic surgery, radiotherapy, stoma status, and treatment‐related body image changes [55, 56, 57]. Reed et al. [58] highlighted the appropriateness of the FSFI tool and emphasised the need for consistent use of validated instruments, while acknowledging that thresholds used to define sexual dysfunction may need to vary by menopausal status (e.g., younger women versus peri‐ or post‐menopausal women). More detailed domain‐level reporting could help identify symptom patterns and support targeted counselling and interventions [59]. International Index of Erectile Function (IIEF) and/or Female Sexual Function Index (FSFI) were the most frequently used sexual function‐specific PROMs, but both are generic instruments and were not developed specifically for cancer populations. They may therefore miss rectal cancer‐specific concerns, including stoma‐related body image, bowel dysfunction during intimacy, radiotherapy effects, relationship context, and altered sexual practices. Cancer‐related QoL tools were also included where sexual function items were extractable, but these were reported inconsistently and often provided limited sexual health detail. Missing contextual factors Key contextual determinants of sexual function were rarely reported, including baseline sexual activity, sexual practices and preferences, sexual orientation, and menopausal status. This limits interpretation for both sexes and is particularly important for women, in whom menopausal transition and treatment‐induced ovarian dysfunction may substantially influence symptoms [17, 60]. The included studies did not directly assess whether relationship changes, reduced or avoided intercourse, or stoma‐related concerns influenced PROM scores; these therefore remain possible explanations. Poor reporting of sexual practices and preferences also limits inclusivity, as many PROMs assume heterosexual, intercourse‐based activity and may not reflect sexual wellbeing across diverse orientations and behaviours [58, 59, 60]. Reasons for PROM non‐completion were also rarely investigated. Embarrassment, reduced sexual activity, relationship changes, and symptom severity are plausible explanations, but their contribution cannot be determined from the available evidence. Heterogeneous follow‐up schedules and incomplete reporting of response rates and missing‐data methods further reduce comparability. Transparent reporting of contextual variables, follow‐up completeness, PROM completion, and missing‐data methods is, therefore, essential. Clinical implications Current evidence may shape survivorship counselling in ways that prioritise male erectile outcomes while under‐addressing female symptoms such as dyspareunia, vaginal dryness, arousal difficulties, and reduced satisfaction. Routine clinical pathways should incorporate proactive, inclusive sexual health discussions, with appropriate referral pathways (e.g., psychosexual services, pelvic floor physiotherapy, menopause services, and counselling). Importantly, limited evidence for women should not be interpreted as evidence of lower symptom burden, particularly when measurement and participation data are incomplete. Strength and limitations This review included diverse study designs and settings and focused on sex‐based reporting disparities. However, heterogeneity in PROMs, outcome definitions, follow‐up, and study quality limited synthesis. Available primary data rarely captured sexual activity, menopausal status, or relationship context. Overall certainty was low because of methodological heterogeneity, incomplete response‐rate reporting, and limited sex‐specific outcome data. Future directions Future rectal cancer survivorship studies should: Prioritise equitable recruitment and retention of women;Investigate strategies to improve the participation of women in studies assessing sexual function;Record and report contextual factors, including sexual activity, sexual practices and preferences, menopausal status, and sexual orientation.Develop a core outcome set for female sexual function after rectal cancer treatment to reduce PROM heterogeneity and improve the consistency, comparability, and clinical relevance of future reporting. Prioritise equitable recruitment and retention of women; Prioritise equitable recruitment and retention of women; Investigate strategies to improve the participation of women in studies assessing sexual function; Investigate strategies to improve the participation of women in studies assessing sexual function; Record and report contextual factors, including sexual activity, sexual practices and preferences, menopausal status, and sexual orientation. Record and report contextual factors, including sexual activity, sexual practices and preferences, menopausal status, and sexual orientation. Develop a core outcome set for female sexual function after rectal cancer treatment to reduce PROM heterogeneity and improve the consistency, comparability, and clinical relevance of future reporting. Develop a core outcome set for female sexual function after rectal cancer treatment to reduce PROM heterogeneity and improve the consistency, comparability, and clinical relevance of future reporting. These steps are necessary to develop an evidence base that accurately reflects the sexual health needs of all patients after rectal cancer treatment. CONCLUSION Sexual function outcomes after rectal cancer treatment are inconsistently reported, with low certainty due to heterogeneous study design, PROMs selection, follow‐up timing, response rates, and incomplete sex‐specific reporting. Although the lower proportion of female participants may partly reflect the male predominance of rectal cancer, limited female‐specific PROMs use and domain‐level reporting suggest that epidemiology alone does not explain the existing reporting gap. Future research should use standardised, sex‐specific and cancer‐relevant outcomes, with development of a core outcome set for female sexual function after rectal cancer treatment. AUTHOR CONTRIBUTIONS Jared Torkington: Writing – review and editing; supervision. Julie A. Cornish: Conceptualization; writing – review and editing; methodology; supervision; resources; investigation; data curation. Vignesh Lakshmanan: Conceptualization; investigation; writing – original draft; methodology; validation; writing – review and editing; formal analysis; data curation; project administration; resources. Jennifer Waterman: Investigation; writing – review and editing; data curation. Alun Meggy: Writing – review and editing. FUNDING INFORMATION No specific funding was received for this work. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT This study was a systematic review and narrative synthesis of previously published literature. CLINICAL TRIAL REGISTRATION This review was registered with PROSPERO (CRD420251178502). Supporting information File S1. Search syntax. File S2. Modified Methodological Items for Non‐Randomised Studies (MINORS) tool—Adapted for this systematic review.